



# Best of 19<sup>th</sup> IASLC World Conference on Lung Cancer (WCLC) 2018

February 2 | 2019  
Royal Olympic Hotel  
Athens | Greece

Licensed by  
**IASLC**  
INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER  
Improving Through Science Worldwide



**EPEIKO**  
ΕΠΕΙΧΟΝΙΟ ΚΑΙ ΕΡΑΣΜΕΥΣΙΝΟ ΙΝΣΤΙΤΟΥΤΟ  
ΕΛΛΗΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ

## Σάββατο 2 Φεβρουαρίου 2019

**16:40-17:45 Small Cell Lung Cancer, Mesothelioma, Thymomas**

Chairs: G. Koumakis, **N. Kentepozidis**

16:40-17:00: Presenter: **A. Tzovaras**

- OA13.01 THE IMPACT OF [18F]FLUDEOXYGLUCOSE PET/CT IN SMALLCELL LUNG CANCER: ANALYSIS OF THE PHASE 3 CONVERT TRIAL
- OA13.02 TWO NOVEL IMMUNOTHERAPY AGENTS TARGETING DLL3 IN SCLC: TRIALS IN PROGRESS OF AMG 757 AND AMG 119
- OA13.03 ANLOTINIB AS THIRD-LINE OR FURTHER-LINE TREATMENT IN RELAPSED SCLC: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND PHASE 2 TRIAL
- 

17:00-17:20: Presenter: **I. Litos**

- OA13.07 SURVIVAL OUTCOMES AFTER WHOLE BRAIN RADIOTHERAPY FOR BRAIN METASTASES IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED METASTATIC SMALL CELL CARCINOMA
- OA08.01 LONG-TERM EFFICACY AND SAFETY OF NIVOLUMAB IN SECOND- OR THIRD-LINE JAPANESE MALIGNANT PLEURAL MESOTHELIOMA PATIENTS (PHASE II: MERIT STUDY)
- OA08.03 PHASE II TRIAL OF PEMBROLIZUMAB (NCT02399371) IN PREVIOUSLY-TREATED MALIGNANT MESOTHELIOMA (MM): FINAL ANALYSIS

17:20-17:35: Presenter: **T. Bilidas**

- OA11.02 A POPULATION-BASED STUDY OF INCIDENCE AND SURVIVAL TRENDS OF 1,588 THYMIC MALIGNANCIES: RESULTS FROM THE CALIFORNIA CANCER REGISTRY